Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene

Susana Puig, Anna Ruiz, Teresa Castel, Victor Volpini, Josep Malvehy, Francesc Cardellach, Michael Lynch, Jose M. Mascaro, Xavier P. Estivill

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Genetic predisposition plays an important role in the development of nearly 10% of cases of cutaneous malignant melanoma (CMM). The CDKN2A gene has been described as responsible for melanoma susceptibility in a proportion of families with CMM linked to 9p. CDKN2A encodes a cyclin-dependent kinase inhibitor also implicated in the carcinogenesis of several sporadic tumors. Even though the incidence of other cancers is higher in CMM families, pancreatic adenocarcinoma is the only other well demonstrated cancer associated with CDKN2A mutations in some CMM pedigrees. We describe a family with four cases of CMM, eight patients affected by other cancers, and nine patients affected by dysplastic nevus (DN) syndrome. A CDKN2A frameshift mutation (358delG) was present in all the CMM patients, in at least three of the patients with other cancers (CDKN2A status is unknown in four patients), and in only two of the DN patients (CDKN2A status is unknown in one patient). An absence of linkage between chromosome 9p markers and the 358delG CDKN2A mutation and DN was detected, indicating genetic heterogeneity for DN and CMM in this family. The study strongly suggests that CDKN2A mutations are involved not only in the predisposition to CMM but also to several other types of cancer.

Original languageEnglish
Pages (from-to)359-364
Number of pages6
JournalHuman Genetics
Volume101
Issue number3
DOIs
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Dysplastic Nevus Syndrome
p16 Genes
Melanoma
Mutation
Neoplasms
Frameshift Mutation
Genetic Heterogeneity
Cyclin-Dependent Kinases
Cutaneous Malignant Melanoma
Pedigree
Genetic Predisposition to Disease
Genetic Markers
Carcinogenesis
Adenocarcinoma

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. / Puig, Susana; Ruiz, Anna; Castel, Teresa; Volpini, Victor; Malvehy, Josep; Cardellach, Francesc; Lynch, Michael; Mascaro, Jose M.; Estivill, Xavier P.

In: Human Genetics, Vol. 101, No. 3, 1997, p. 359-364.

Research output: Contribution to journalArticle

Puig, Susana ; Ruiz, Anna ; Castel, Teresa ; Volpini, Victor ; Malvehy, Josep ; Cardellach, Francesc ; Lynch, Michael ; Mascaro, Jose M. ; Estivill, Xavier P. / Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. In: Human Genetics. 1997 ; Vol. 101, No. 3. pp. 359-364.
@article{41993775117d4780b9d0842341d925db,
title = "Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene",
abstract = "Genetic predisposition plays an important role in the development of nearly 10{\%} of cases of cutaneous malignant melanoma (CMM). The CDKN2A gene has been described as responsible for melanoma susceptibility in a proportion of families with CMM linked to 9p. CDKN2A encodes a cyclin-dependent kinase inhibitor also implicated in the carcinogenesis of several sporadic tumors. Even though the incidence of other cancers is higher in CMM families, pancreatic adenocarcinoma is the only other well demonstrated cancer associated with CDKN2A mutations in some CMM pedigrees. We describe a family with four cases of CMM, eight patients affected by other cancers, and nine patients affected by dysplastic nevus (DN) syndrome. A CDKN2A frameshift mutation (358delG) was present in all the CMM patients, in at least three of the patients with other cancers (CDKN2A status is unknown in four patients), and in only two of the DN patients (CDKN2A status is unknown in one patient). An absence of linkage between chromosome 9p markers and the 358delG CDKN2A mutation and DN was detected, indicating genetic heterogeneity for DN and CMM in this family. The study strongly suggests that CDKN2A mutations are involved not only in the predisposition to CMM but also to several other types of cancer.",
author = "Susana Puig and Anna Ruiz and Teresa Castel and Victor Volpini and Josep Malvehy and Francesc Cardellach and Michael Lynch and Mascaro, {Jose M.} and Estivill, {Xavier P.}",
year = "1997",
doi = "10.1007/s004390050642",
language = "English",
volume = "101",
pages = "359--364",
journal = "Human Genetics",
issn = "0340-6717",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene

AU - Puig, Susana

AU - Ruiz, Anna

AU - Castel, Teresa

AU - Volpini, Victor

AU - Malvehy, Josep

AU - Cardellach, Francesc

AU - Lynch, Michael

AU - Mascaro, Jose M.

AU - Estivill, Xavier P.

PY - 1997

Y1 - 1997

N2 - Genetic predisposition plays an important role in the development of nearly 10% of cases of cutaneous malignant melanoma (CMM). The CDKN2A gene has been described as responsible for melanoma susceptibility in a proportion of families with CMM linked to 9p. CDKN2A encodes a cyclin-dependent kinase inhibitor also implicated in the carcinogenesis of several sporadic tumors. Even though the incidence of other cancers is higher in CMM families, pancreatic adenocarcinoma is the only other well demonstrated cancer associated with CDKN2A mutations in some CMM pedigrees. We describe a family with four cases of CMM, eight patients affected by other cancers, and nine patients affected by dysplastic nevus (DN) syndrome. A CDKN2A frameshift mutation (358delG) was present in all the CMM patients, in at least three of the patients with other cancers (CDKN2A status is unknown in four patients), and in only two of the DN patients (CDKN2A status is unknown in one patient). An absence of linkage between chromosome 9p markers and the 358delG CDKN2A mutation and DN was detected, indicating genetic heterogeneity for DN and CMM in this family. The study strongly suggests that CDKN2A mutations are involved not only in the predisposition to CMM but also to several other types of cancer.

AB - Genetic predisposition plays an important role in the development of nearly 10% of cases of cutaneous malignant melanoma (CMM). The CDKN2A gene has been described as responsible for melanoma susceptibility in a proportion of families with CMM linked to 9p. CDKN2A encodes a cyclin-dependent kinase inhibitor also implicated in the carcinogenesis of several sporadic tumors. Even though the incidence of other cancers is higher in CMM families, pancreatic adenocarcinoma is the only other well demonstrated cancer associated with CDKN2A mutations in some CMM pedigrees. We describe a family with four cases of CMM, eight patients affected by other cancers, and nine patients affected by dysplastic nevus (DN) syndrome. A CDKN2A frameshift mutation (358delG) was present in all the CMM patients, in at least three of the patients with other cancers (CDKN2A status is unknown in four patients), and in only two of the DN patients (CDKN2A status is unknown in one patient). An absence of linkage between chromosome 9p markers and the 358delG CDKN2A mutation and DN was detected, indicating genetic heterogeneity for DN and CMM in this family. The study strongly suggests that CDKN2A mutations are involved not only in the predisposition to CMM but also to several other types of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031448010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031448010&partnerID=8YFLogxK

U2 - 10.1007/s004390050642

DO - 10.1007/s004390050642

M3 - Article

VL - 101

SP - 359

EP - 364

JO - Human Genetics

JF - Human Genetics

SN - 0340-6717

IS - 3

ER -